Mosnodenvir (JNJ-1802) is a pan-serotype dengue antiviral agent with a high barrier to resistance, and is safe and well-tolerated. Mosnodenvir blocks the NS3-NS4B interaction within the viral replication complex. Mosnodenvir shows picomolar to low nanomolar in vitro antiviral activity in mice.
References:
[1]. Ackaert O, et al. Safety, tolerability and pharmacokinetics of JNJ-1802, a pan-serotype dengue direct antiviral small molecule, in a Phase 1, double-blind, randomized, dose-escalation study in healthy volunteers. Clin Infect Dis. 2023 May 10:ciad284.
[2]. Goethals O, et al. Blocking NS3-NS4B interaction inhibits dengue virus in non-human primates. Nature. 2023 Mar;615(7953):678-686.
















